Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-12-13FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental abbreviated new drug application for duloxetine hydrochloride from Aurobindo Pharma Limited (ANDA 090778), e…
-
FDA approval · 2019-12-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s supplemental application for quetiapine fumarate, a generic formulation under ANDA 090749.
-
FDA approval · 2019-12-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for Quetiapine Fumarate (ANDA 090120).
-
FDA approval · 2019-12-10FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for ARIPIPRAZOLE from Amneal Pharmaceuticals LLC (aripiprazole).
-
FDA approval · 2019-12-10FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved Upsher-Smith Laboratories' supplemental application for bupropion hydrochloride, updating the product labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder [Phase 2]
Phase 2 study evaluating TS-121 as adjunctive treatment for major depressive disorder was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-12-06Clinical Trial Update: Using the LENA System in Early Intervention - b [NA]
A completed clinical trial investigating the LENA System in early intervention for depression; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression [Phase 4]
Phase 4 trial looking at melancholic depression and insomnia as predictors of response to quetiapine in patients with major depressive disor…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression [Phase 2]
Phase 2 trial of repeated ketamine infusions demonstrates efficacy in treatment-resistant depression. The results were posted on December 3,…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
A completed clinical trial studying caregiver burden and distress in hematopoietic stem cell transplant, focusing on depression, anxiety, fa…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 2) [NA]
Phase 2 trial update on integrating mindfulness into patient-centered medical home for depression and anxiety with completed status and resu…
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients [Phase 4]
Phase 4 trial comparing electroconvulsive therapy (ECT) alone versus ECT plus agomelatine for major depressive disorder; study completed.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users [Phase 4]
Phase 4 trial comparing MBRP plus vortioxetine versus MBRP alone for relapse prevention in chronic methamphetamine users.
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Open Label Extension for GLYX13-C-202, NCT01684163 [Phase 2]
Open-label extension of a Phase 2 study for GLYX13 in major depressive disorder has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Internet-guided Cognitive Behavioural Therapy to Improve Depression Patients With Cardiovascular Disease [NA]
Completed clinical trial evaluating internet-guided cognitive-behavioral therapy for patients with cardiovascular disease and depression; re…
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression [Phase 3]
Phase 3 trial of combined prolonged exposure therapy and pramipexole for PTSD and major depressive disorder was terminated with posted resul…
-
FDA approval · 2019-11-22FDA Approved: MIRTAZAPINE — Supplemental Application (Aurolife Pharma LLC)
The FDA approved a supplemental application for mirtazapine from Aurolife Pharma LLC, enabling the marketed generic to proceed under an appr…
-
FDA approval · 2019-11-22FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approves a supplemental application for Quetiapine by Accord Healthcare Inc., granting regulatory approval for a generic version of the …
-
FDA approval · 2019-11-22FDA Approved: MIRTAZAPINE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application to market a generic mirtazapine product.
-
FDA approval · 2019-11-20FDA Approved: MIRTAZAPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for mirtazapine, allowing a generic version to come to market under the…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated omega-3 fatty acids as a personalized treatment approach for major depressive disorder with high infla…
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Transcranial Magnetic Stimulation for Adolescent Depression [NA]
Completed clinical trial evaluating transcranial magnetic stimulation for adolescent major depressive disorder; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) [Phase 2]
Phase 2 trial evaluating adjunctive pimavanserin for major depressive disorder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) [Phase 3]
Phase 3 clinical trial update for rapastinel as adjunctive therapy in major depressive disorder has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder [Phase 4]
Phase 4 trial evaluating all-cause hospitalizations for Abilify MyCite users versus virtual matched controls in adults with schizophrenia, b…